UPTRAVI: payments to doctors
Payments that named UPTRAVI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $18.6M
- Providers
- 26,325
- Transactions
- 140,458
- Average per transaction
- $133
The per-transaction average — $133 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 26,325 providers the average total is $708, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $18,433,951 | 98.9% |
| Johnson & Johnson | $163,468 | 0.9% |
| Janssen Scientific Affairs, LLC | $23,563 | 0.1% |
| Actelion Pharmaceuticals, Ltd | $9,033 | 0.0% |
| Nippon Shinyaku Co.,ltd | $2,541 | 0.0% |
| Janssen Research & Development, LLC | $164 | 0.0% |